Shin-Ichi Fuchida

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Venues

Cancer immunology, immunotherapy : CII

International journal of hematology

Cancer science

EJHaem

This page only lists publications with an associated author ORCID identifier.

Publications

Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII 73 (7) (2024)
Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII 73 (7) (2024)
Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII 73 (7) (2024)
Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII 73 (7) (2024)
Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-Ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients. Cancer immunology, immunotherapy : CII 73 (7) (2024)
Shin-Ichi Fuchida, Mizuki Ogura, Tadao Ishida, Hiroyuki Hata, Hiroshi Handa, Nagaaki Katoh, Chiaki Nakaseko, Kazutaka Sunami, Yuta Katayama, Hironobu Nobata, Kazuiku Oshiro, Shinsuke Iida, Yoshiki Sekijima, Hironobu Naiki, Chihiro Shimazaki
A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee. International journal of hematology (2023)
Chihiro Shimazaki, Saori Matsui-Maegawa, Yayoi Kimoto-Matsumura, Saeko Ota-Kuwabara, Daisuke Ide, Shin-Ichi Fuchida, Mayumi Hatsuse
The serum level of plasmin-alpha2 plasmin inhibitor complex (PIC) is useful for differentiating cardiac light chain amyloidosis from transthyretin amyloidosis. British journal of haematology (2023)
Yutaka Shimazu, Shohei Mizuno, Shin-Ichi Fuchida, Kazuhito Suzuki, Nobuhiro Tsukada, Akira Hanagaishi, Mitsuhiro Itagaki, Keisuke Kataoka, Shinichi Kako, Emiko Sakaida, Satoshi Yoshioka, Shinsuke Iida, Noriko Doki, Tatsuo Oyake, Tatsuo Ichinohe, Yoshinobu Kanda, Yoshiko Astuta, Hiroyuki Takamatsu, null null
Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine. Cancer science 112 (12) (2021)
Aya Nakaya, Hirohiko Shibayama, Eiji Nakatani, Yuji Shimura, Satoru Kosugi, Hirokazu Tanaka, Shin-Ichi Fuchida, Junya Kanda, Nobuhiko Uoshima, Hitomi Kaneko, Kazunori Imada, Kensuke Ohta, Tomoki Ito, Hideo Yagi, Satoshi Yoshihara, Masayuki Hino, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura
Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum. EJHaem 2 (4) (2021)
Shin-Ichi Fuchida, Daisuke Ide, Yoko Taminishi-Katsuragawa, Takaomi Suga, Saori Matsui-Maegawa, Naoki Maruyama, Yumi Iwamura, Yohei Kitamura, Yoshifumi Okawa, Akira Okano, Mayumi Hatsuse, Satoshi Murakami, Chihiro Shimazaki
A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan. International journal of hematology 111 (6) (2020)

Shin-Ichi Fuchida.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Shin-Ichi Fuchida